Who invested in Endeavor BioMedicines

One round we have observed, with the 3 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$133Mraised across 1 round since 2024, from 1 source

Latest round: Series C, $133MApr 2024
Investors: 3

See who backed them

The rounds

Apr 2024
Series C$133M
Source recordedSEC filing: $133M sold, first sale Apr 2024

Founders and team

From Endeavor BioMedicines's own website and the SEC filings it signed: 9 on the team.

Anita DiFrancescoSenior Vice President, Clinical Operations
Betsy GelfandSenior Vice President, Finance
Hutch HumphreysVice President, Regulatory Affairs
Randy AdamsSenior Vice President, Strategic Marketing & Communications
Vishaal TurakhiaChief Financial Officer
Chris KruegerExecutive Officeri
Enoch KariukiExecutive Officeri
John HoodExecutive Officer, Directori
Miguel de los RiosExecutive Officeri

On the board, as filediBernard DavitianKaran Cheong TakharMonal Cheong MehtaPatrick G. EnrightWing Cheong Lam

Everyone who backed them

FidelityVC firm1round

Perceptive AdvisorsAsset manager1round

Omega FundsVC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists Endeavor BioMedicines as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.